低热量甜味剂(LCS)提供甜味,能量很少或没有。然而,每个LCS的独特化学结构都有可能引发不同的感官,生理,和影响体重的行为反应。
本试验的目的是比较食用4种LCSs和蔗糖对体重的影响,摄食行为,对超重或肥胖(体重指数25-40kg/m2)的成年人(18-60岁)进行12周干预的葡萄糖耐量。
在平行臂设计中,154名参与者被随机分配食用1.25-1.75L蔗糖增甜的饮料(n=39),阿斯巴甜(n=30),糖精(n=29),三氯蔗糖(n=28),或莱鲍迪甙A(rebA)(n=28),每天12周。饮料含有400-560kcal/d(蔗糖处理)或<5kcal/d(LCS处理)。人体测量指标,能量摄入,能量消耗,食欲,在基线时测量葡萄糖耐量。每2周用能量摄入测量体重,支出,每4周评估一次食欲。每4周完成24小时尿液收集,以确定通过对氨基苯甲酸排泄的研究依从性。
在参加试验的参与者中,123完成了12周的干预。蔗糖和糖精的消耗导致12周干预期间的体重增加(Δ体重=1.85±0.36kg和1.18±0.36kg,分别;P≤0.02),彼此之间没有差异。与基线相比,随着其他LCS治疗的消耗,体重没有显著变化,但是在第12周时,三氯蔗糖的体重变化为负,并且与所有其他LCS相比显着降低(体重差异≥1.37±0.52kg,P≤0.008)。能量摄入随着三氯半乳蔗糖的消耗而减少(P=0.02),三氯半乳蔗糖的摄入频率低于糖精(P=0.045)。葡萄糖耐量不受任何甜味剂处理的显著影响。
与阿斯巴甜相比,蔗糖和糖精的消费显著增加体重,雷帕,和三氯蔗糖,而与糖精相比,三氯蔗糖的体重变化在方向上是负的,并且较低,阿斯巴甜,和reba消费。由于LCS对体重的影响不同,因此应将其归类为不同的实体。该试验在clinicaltrials.gov注册为NCT02928653。
Low-calorie sweeteners (LCSs) provide sweetness with little or no energy. However, each LCS\'s unique chemical structure has potential to elicit different sensory, physiological, and behavioral responses that affect body weight.
The purpose of this
trial was to compare the effects of consumption of 4 LCSs and sucrose on body weight, ingestive behaviors, and glucose tolerance over a 12-wk intervention in adults (18-60 y old) with overweight or obesity (body mass index 25-40 kg/m2).
In a parallel-arm design, 154 participants were randomly assigned to consume 1.25-1.75 L of beverage sweetened with sucrose (n = 39), aspartame (n = 30), saccharin (n = 29), sucralose (n = 28), or rebaudioside A (rebA) (n = 28) daily for 12 wk. The beverages contained 400-560 kcal/d (sucrose treatments) or <5 kcal/d (LCS treatments). Anthropometric indexes, energy intake, energy expenditure, appetite, and glucose tolerance were measured at baseline. Body weight was measured every 2 wk with energy intake, expenditure, and appetite assessed every 4 wk. Twenty-four-hour urine collections were completed every 4 wk to determine
study compliance via para-aminobenzoic acid excretion.
Of the participants enrolled in the
trial, 123 completed the 12-wk intervention. Sucrose and saccharin consumption led to increased body weight across the 12-wk intervention (Δweight = +1.85 ± 0.36 kg and +1.18 ± 0.36 kg, respectively; P ≤ 0.02) and did not differ from each other. There was no significant change in body weight with consumption of the other LCS treatments compared with baseline, but change in body weight for sucralose was negative and significantly lower compared with all other LCSs at week 12 (weight difference ≥ 1.37 ± 0.52 kg, P ≤ 0.008). Energy intake decreased with sucralose consumption (P = 0.02) and ingestive frequency was lower for sucralose than for saccharin (P = 0.045). Glucose tolerance was not significantly affected by any of the sweetener treatments.
Sucrose and saccharin consumption significantly increase body weight compared with aspartame, rebA, and sucralose, whereas weight change was directionally negative and lower for sucralose compared with saccharin, aspartame, and rebA consumption. LCSs should be categorized as distinct entities because of their differing effects on body weight. This
trial was registered at clinicaltrials.gov as NCT02928653.